Brian Skorney
Stock Analyst at Baird
(3.51)
# 868
Out of 4,876 analysts
111
Total ratings
46.15%
Success rate
6.2%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $9.57 | +234.38% | 2 | Jun 18, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $60 → $30 | $17.11 | +75.34% | 10 | Jun 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $102 → $105 | $83.22 | +26.17% | 4 | May 8, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $126.08 | +102.25% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $521.00 | +12.67% | 15 | Apr 30, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $57 | $14.09 | +304.54% | 3 | Apr 28, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $51.07 | +7.70% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $110.67 | -9.64% | 3 | Feb 12, 2025 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $11.35 | +164.32% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.32 | +1,444.16% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $7.50 | +166.67% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.02 | +727.81% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $2.31 | +332.90% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $277.13 | -22.42% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $125.42 | +43.52% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $4.12 | +579.61% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $29.96 | +106.94% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.40 | +364.29% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $32.40 | +94.44% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $441.30 | -26.35% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $16.10 | -37.89% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $1.97 | +13,605.58% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $2.96 | +102.70% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $2.17 | +13,724.88% | 3 | May 7, 2018 |
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $9.57
Upside: +234.38%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Outperform
Price Target: $60 → $30
Current: $17.11
Upside: +75.34%
Soleno Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $102 → $105
Current: $83.22
Upside: +26.17%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $126.08
Upside: +102.25%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $521.00
Upside: +12.67%
Biohaven
Apr 28, 2025
Maintains: Outperform
Price Target: $60 → $57
Current: $14.09
Upside: +304.54%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $51.07
Upside: +7.70%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $110.67
Upside: -9.64%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $11.35
Upside: +164.32%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.32
Upside: +1,444.16%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $7.50
Upside: +166.67%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $3.02
Upside: +727.81%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $2.31
Upside: +332.90%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $277.13
Upside: -22.42%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $125.42
Upside: +43.52%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $4.12
Upside: +579.61%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $29.96
Upside: +106.94%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.40
Upside: +364.29%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $32.40
Upside: +94.44%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $441.30
Upside: -26.35%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $16.10
Upside: -37.89%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $1.97
Upside: +13,605.58%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $2.96
Upside: +102.70%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $2.17
Upside: +13,724.88%